Clinical Study Of Shenling Prescription In The Treatment Of TACE Syndrome Of Primary Liver Cancer

Objective: In this study,the effect of Shenling prescription on the syndrome after hepatic artery chemoembolization(TACE)for primary liver cancer was observed,and its clinical efficacy was objectively evaluated,so as to provide a basis for the clinical application of Shenling prescription.Methods: Sixty-six patients diagnosed with primary liver cancer and treated with TACE in the Department of Oncology of Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine from January 2020 to February 2021 were randomly divided into treatment group and control group according to the random number table method,with 33 patients in each group and no cases of falling out.After TACE,the control group was given conventional western medicine treatment(antipyretic,analgesic,antinausea,liver protection,stomach protection,etc.),and the treatment group was given Shenling formula decoction on the basis of the treatment in the control group,with a course of 1 week.The incidence and duration of fever,liver pain,nausea and vomiting from the first day to the seventh day after surgery were observed and recorded in both groups.The TCM clinical symptoms of the two groups were observed and recorded on the 1st and 7th day after operation.Liver function(ALT,AST,TBIL)before and 7 days after surgery were recorded in both groups.Alpha fetoprotein(AFP);Prothrombin time(PT);Quality of life: KPS score;Abdominal CT results of patients in both groups were recorded before and 1 month after surgery.SPSS25.0 software was used for data analysis,and changes in fever,liver pain,nausea and vomiting degree,duration,TCM symptom score,TCM symptom efficacy,liver function(ALT,AST,TBIL),AFP,prothrombin time(PT),tumor size and KPS score were compared between 2 groups.Results: 1.Baseline data: Before treatment,there were no statistically significant differences in gender,age,Child-Pugh liver function grade,disease stage and KPS score between the two groups(P>0.05),indicating comparability.2.Symptom indicators: there was no statistical significance in the degree of fever,liver pain,nausea and vomiting between the two groups on the 1st and 2nd day after TACE(P>0.05).There were statistically significant differences in fever,liver pain,nausea and vomiting between the two groups from the 3rd day to the 7th day after TACE,and the treatment group was better than the control group(P<0.05).There were statistically significant differences in the duration of fever,liver pain,nausea and vomiting symptoms between the two groups,and the duration of symptoms in the treatment group was shorter than that in the control group(P<0.05).The TCM symptom scores in both groups on the 7th day after surgery were lower than those on the 1st day after surgery,and there was statistical significance in the intra-group comparison of TCM symptom scores in both groups(P<0.05).There was statistical significance in TCM symptom score between 2groups(P<0.05).The improvement of TCM symptoms in the treatment group was better than that in the control group.The total effective rate of the treatment group was 78.79%,and the total effective rate of the control group was 54.55%.The difference between the two groups was statistically significant(P<0.05),and the treatment group was better than the control group.3.Laboratory indicators: there was no significant difference in ALT,AST and TBIL between the two groups before treatment(P>0.05),indicating comparability;The differences in ALT,AST and TBIL between 2 groups were statistically significant(P<0.05).After treatment,there were statistically significant differences in ALT,AST and TBIL between 2 groups(P<0.05).The improvement of ALT,AST and TBIL in the treatment group was better than that in the control group.There was no significant difference in the levels of PT and AFP between the two groups before treatment(P>0.05),while there was no significant difference in the levels of PT and AFP between the two groups after treatment(P>0.05),indicating that there was no significant difference in the levels of PT and AFP between the two groups before and after treatment.4.Tumor efficacy: there was no statistically significant difference in the efficacy of solid tumor between the two groups(P>0.05).5.Quality of life: there was no statistically significant difference in KPS scores between 2 groups before treatment(P>0.05);After treatment,there was a statistically significant difference in KPS score between the two groups(P<0.05),and the treatment group was better than the control group.Conclusion: Shenling prescription can alleviate TACE syndrome of primary liver cancer,improve the symptoms of traditional Chinese medicine,promote the repair of liver function,and improve the quality of life of patients.